Pain Therapeutics' Window of Opportunity
This article was originally published in Start Up
Pain Therapeutics Inc., which started up in 1998 and went public just two years later in a hot market, thinks it can turn Purdue Pharma's patent problems to its own advantage-and go it one better. Long before the OxyContin patents were deemed invalid, Purdue was struggling with the fact that its extended-release painkiller had become a drug of abuse. People looking for a quick high found they could get one by crushing "Oxies" or dissolving them in alcohol--thus circumventing the innovation in formulation that made OxyContin so effective at treating pain. Pain Therapeutics believes it has a way around the abuse problem.
You may also be interested in...
The envy that many people in the biotech and pharma industry felt in the late 1990s when Purdue Pharma's revenues skyrocketed on sales of OxyContin was replaced by compassion, as the company struggled to deal with illegal use and abuse of the painkiller. Now Purdue is battlling a court ruling--sparked by would-be generic competitor Endo Pharmaceuticals--that finds the patents on Purdue's most important product are unenforceable. The company is confident it will prevail and enjoy another nine years of patent protection for OxyContin.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.